Understanding the Importance of Tumour Stiffness in Cancer Progression

Cancer tumours are not just clusters of rogue cells; they undergo profound mechanical changes as they develop. One of the most telling signs of malignancy is increased tissue stiffness. This hardening occurs primarily due to alterations in the extracellular matrix (ECM), a scaffold-like network of proteins and fibres surrounding cells. In healthy tissue, the ECM provides structural support, but in tumours, it becomes denser and more crosslinked, often dominated by collagen fibres.

Why does this matter? Stiff tumours hinder the delivery of oxygen and nutrients, leading to hypoxic (low-oxygen) regions that make cancer cells more resistant to chemotherapy and radiotherapy. Moreover, rigidity promotes invasiveness, enabling cancer cells to break away and metastasize. Immune cells also struggle to penetrate stiff barriers, weakening the body's natural defences. Measuring tumour stiffness non-invasively thus offers a window into these processes, helping researchers track progression and evaluate therapies that target the mechanical microenvironment.

Traditional imaging like MRI or CT excels at anatomy but falls short on biomechanics. Ultrasound-based elastography techniques emerged to fill this gap, quantifying stiffness by tracking how tissues respond to mechanical stress. Shear wave elastography (SWE), in particular, generates shear waves—transverse vibrations—and measures their speed (shear wave speed, SWS), where faster speeds indicate stiffer tissue. Yet, in preclinical models—small tumours in mice—challenges like motion from breathing and tiny sizes have limited repeatability.

📡 Introducing Vibrational Shear Wave Elastography (VSWE)

Vibrational Shear Wave Elastography (VSWE) represents a leap forward, pioneered by researchers at The Institute of Cancer Research (ICR), London. Unlike conventional SWE, which uses ultrasound 'push pulses' to generate waves internally, VSWE applies continuous external vibrations via a mechanical actuator coupled to the skin. This allows precise control over frequency and amplitude, crucial for penetrating small, attenuating tumours.

High-frequency ultrasound (around 18 MHz) captures the propagating waves in 3D by scanning slices and reconstructing volumetric maps. SWS maps reveal heterogeneity—stiff rims versus softer cores—mirroring histopathological changes. ICR's team, including Professor Jeff Bamber and Dr. Emma Harris, has refined VSWE for preclinical use, addressing limitations of magnetic resonance elastography (MRE), which is costly and slow.

Preclinical validation began in 2022 with 3D-VSWE on glioblastoma (U-87 MG) and breast cancer (MDA-MB-231) xenografts in mice. The technique detected therapy-induced softening post anti-vascular drug ZD6126, with SWS drops of 24.7% and 12.3% respectively, correlating to 86-92% necrosis versus 16-30% in controls. Repeatability was excellent, with within-subject coefficients of variation (CV) under 6.4%.

The Groundbreaking ICR Study on VSWE Repeatability

Published in February 2026 in Physics in Medicine & Biology, the latest ICR study by John Civale, Vaideesh Parasaram, and colleagues rigorously tested VSWE's reliability in real-world preclinical scenarios. Four mice bearing human breast cancer flank tumours (~500 mm³) underwent imaging over three days, yielding 138 datasets.

Variables tested included vibration frequencies (500 Hz and 1000 Hz), tumour orientations, and anaesthetics affecting breathing motion. At 500 Hz, variability was minimal with deep wave penetration; 1000 Hz showed higher variability due to attenuation. Crucially, anaesthesia and orientation barely impacted results, and inter-tumour stiffness differences were statistically significant and consistent.

3D SWS maps correlated highly across days, with stable spatial patterns despite growth. First author John Civale noted, “The day-to-day consistency was remarkably strong despite imaging complexities.” Senior author Dr. Emma Harris added, “This provides a benchmark for elastography studies, accelerating stiffness-targeted therapies.” Supported by Cancer Research UK, the work underscores VSWE's robustness.Read the full ICR announcement.

• Lowest variability at 500 Hz for optimal penetration in tumour tissue.
• Resilient to breathing motion, ideal for longitudinal studies.
• Detects subtle mechanical changes before volume shrinkage.
• 3D mapping reveals heterogeneity as a potential biomarker.

🔬 How VSWE Works: A Step-by-Step Technical Overview

For those new to biomechanics, VSWE operates on wave physics principles. External vibrators (700-1200 Hz) induce shear waves that propagate slower in soft tissue (~4 m/s baseline) and faster in stiff regions. An 18.5 MHz probe acquires radiofrequency data in step-and-shoot mode, building 3D phase maps via autocorrelation (2 mm kernel).

Quality metrics like Conformance (energy at drive frequency) and Goodness of Fit ensure accuracy. Reconstruction yields colour-coded SWS maps: blue for soft (necrotic), red for stiff (viable/invasive). Scans take under 5 minutes for 15 mm volumes, enabling frequent monitoring.

This tunability surpasses pulse-based methods, positioning VSWE as a preclinical powerhouse.

Preclinical Success and Therapeutic Insights

Building on 2022 findings in Cancers, where VSWE mapped post-therapy necrosis,view the open-access paper, the 2026 study confirms its utility. Stiffness reductions preceded shrinkage by weeks, an edge over RECIST criteria (Response Evaluation Criteria in Solid Tumours).

Applications span drug screening: ECM-targeting agents (e.g., collagenase) or anti-fibrotics could be assessed early. In radiotherapy, stiffness predicts fibrosis risk. For immunotherapy, softer tumours may enhance T-cell infiltration.

ICR seeks industry partners for commercialization, with UK patent GB2214230.1 filed.Explore collaboration opportunities.

Towards Clinical Translation and Broader Impacts

ICR's VSWE clinical trial (NCT07098819) evaluates lymph node stiffness, where cancer stiffens nodes.Trial details. Human adaptation could aid breast, prostate, and liver cancer staging, personalizing treatments.

In UK higher education, this exemplifies translational research at ICR, affiliated with University of London. It highlights interdisciplinary roles: physicists, engineers, oncologists. Funding from CRUK and EPSRC fuels such innovations, boosting global rankings.

For aspiring researchers, VSWE opens doors in biomedical imaging. Explore research jobs or clinical research jobs in the UK to contribute.

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Future Directions and Opportunities in Cancer Biomechanics

Next steps include advanced image registration for growth compensation and multi-frequency dispersion analysis for viscoelasticity. Integration with AI could automate analysis, enhancing precision.

This advance positions UK academia at the forefront of mechanobiology, potentially improving patient outcomes via better preclinical-to-clinical pipelines. Students and professors in radiology or oncology can leverage such tools for theses or grants.

Rate your professors on Rate My Professor to share insights from biomechanics courses. Searching for roles? Check higher ed jobs, including lecturer jobs and professor jobs in cutting-edge fields. Craft a winning academic CV to join teams like ICR's. Stay informed and have your say in the comments below.